Journal of Medicinal Chemistry p. 3973 - 4001 (2010)
Update date:2022-08-16
Topics:
Adams, Nicholas D.
Adams, Jerry L.
Burgess, Joelle L.
Chaudhari, Amita M.
Copeland, Robert A.
Donatelli, Carla A.
Drewry, David H.
Fisher, Kelly E.
Hamajima, Toshihiro
Hardwicke, Mary Ann
Huffman, William F.
Koretke-Brown, Kristin K.
Lai, Zhihong V.
McDonald, Octerloney B.
Nakamura, Hiroko
Newlander, Ken A.
Oleykowski, Catherine A.
Parrish, Cynthia A.
Patrick, Denis R.
Plant, Ramona
Sarpong, Martha A.
Sasaki, Kosuke
Schmidt, Stanley J.
Silva, Domingos J.
Sutton, David
Tang, Jun
Thompson, Christine S.
Tummino, Peter J.
Wang, Jamin C.
Xiang, Hong
Yang, Jingsong
Dhanak, Dashyant
The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.
View MoreSinoway International (Jiangsu) Co., Ltd.
Contact:+86-25-86630167
Address:17 Beijing Road (West), Nanjing, China
Longhui qunfeng Chemical Co., Ltd
Contact:86-731-82173407
Address:South-east Industrial Park, Longhui County, Hunan Province, China
Contact:+86 21 5017 5386
Address:No 999,Jiangyue Rd, Minhang Dist ,201114,Shanghai ,China
Hangzhou Gangjin Chemical Co.,Ltd.
Contact:+86-571-85109780
Address:707 Zhejiang Minhang Bldg., No.290 Zhongshan North Road, Hangzhou 310003, China
Shanghai shibo Chemical Co., Ltd
Contact:+86-021-60753516
Address:688 Qiushi Road, Jinshan High-tech Park, Shanghai, China,201512
Doi:10.1039/c4cy00021h
(2014)Doi:10.1021/ja00528a062
(1980)Doi:10.1021/acsmedchemlett.0c00649
(2021)Doi:10.1248/cpb.30.3834
(1982)Doi:10.1007/s10562-010-0515-9
(2011)Doi:10.1016/j.tetlet.2013.09.097
(2013)